Secretoneurin (SN) ELISA Assay
Prognosis & Risk Stratification in Heart Failure (HF)
Key Facts
About CardiNor
Founded in 2015, CardiNor is a diagnostics company leveraging the biomarker secretoneurin (SN) to address the unmet need for improved risk stratification and prognosis in heart failure patients. The company achieved CE-IVD registration for its SN ELISA assay in 2021 and is focused on commercializing the test in Europe and the US through established distribution agreements. Following its acquisition by IC Targets AS in 2025, CardiNor aims to integrate its low-cost SN blood test with advanced cardiac MRI imaging for a comprehensive heart failure diagnostic solution.
View full company profileAbout CardiNor
Founded in 2015, CardiNor is a diagnostics company leveraging the biomarker secretoneurin (SN) to address the unmet need for improved risk stratification and prognosis in heart failure patients. The company achieved CE-IVD registration for its SN ELISA assay in 2021 and is focused on commercializing the test in Europe and the US through established distribution agreements. Following its acquisition by IC Targets AS in 2025, CardiNor aims to integrate its low-cost SN blood test with advanced cardiac MRI imaging for a comprehensive heart failure diagnostic solution.
View full company profile